All news

HC Wainwright reiterates Buy on Monte Rosa Therapeutics

Alpha Vantage · TradingView · · AI-summarised by FinFlash

HC Wainwright & Co. reiterated a Buy rating on Monte Rosa Therapeutics (GLUE) with a $25.00 price target, implying 138.1% upside from the recent closing price. The firm cited the company's clinical pipeline targeting immune-mediated diseases and metastatic prostate cancer, along with a probability-adjusted valuation of roughly $2.9 billion. All eight analysts covering the stock rate it Buy, with no Hold or Sell ratings.

Read original source

GLUE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.